Kaitlyn D’Onofrio

DocwireNews

Patients with psoriatic arthritis (PsA) may observe improved long-term outcomes with secukinumab treatment, according to the results of a five-year study.&ldquo;Biologic therapies, such as anti&ndash;tumor necrosis factor (<a href="https://www.docwirenews.com/abstracts/rheumatology-abstracts/real-world-comparative-effectiveness-of-tofacitinib-and-tumor-necrosis-factor-inhibitors-as-monotherapy-and-combination-therapy-for-treatment-of-rheumatoid-arthritis/">TNF</a>) and anti&ndash;interleukin (IL)&#8208;17A antibodies, are recommended for the treatment of PsA in patients who experience an inadequate response to first&#8208;line treatment with nonsteroidal anti&#8208;inflammatory drugs (NSAIDs) and/or disease&#8208;modifying antirheumatic drugs (DMARDs),&rdquo; the researchers explained.Three-year findings from FUTURE 1 observed that secukinumab significantly inhibited joint structural damage through 24 weeks and that the benefits persisted through year three. In this report, researchers presented the five-year efficacy and safety results.Inclusion criteria for FUTURE 1 included PsA patients with moderate to severe symptoms for at least six months, as well as at least three tender joints and three swollen joints at baseline. Anti-TNF inadequate responders (anti-TNF-IR) was defined as achieving no significant benefit from an anti-TNF therapy after three months or terminated treatment due to intolerability issues.The main outcome measure was the long-term efficacy of secukinumab, measured as the proportion of patients achieving 20% or greater, 50% or greater, or 70% or greater improvement in the American College of Rheumatology criteria for improvement (ACR20, ACR50, and ACR70, respectively).Of 236 patients in the secukinumab 150-mg group, 193 (81.8%) finished five years of treatment; of those patients, 36.4% (n = 86/236) escalated from 150 mg to 300 mg. Secukinumab was associated with sustained improvements in all efficacy endpoints over five years; at five years, 71.0% of patients achieved ACR20 responses, 51.8% achieved ACR50 responses, and 36.3% achieved ACR70 responses. Patients who required dose escalation presented improved efficacy comparably with patients who did not require dose escalation. The authors reported the following exposure-adjusted incidence rates per 100-person years for any dose of secukinumab: serious infection, 1.8; Crohn&rsquo;s disease, 0.2; Candida infection, 0.9; and major cardiac adverse events. 0.5. No new safety signals were reported.The study was published in <a href="https://onlinelibrary.wiley.com/doi/full/10.1002/acr2.11097">ACR Open Rheumatology</a>.&ldquo;Results from this long&#8208;term extension study confirm the benefit of IL&#8208;17 inhibition with secukinumab for sustained improvements in the signs and symptoms of major clinical domains of PsA,&rdquo; the study authors concluded. &ldquo;With no new safety concerns over a treatment period of up to 5 years, results from the 5&#8208;year phase III FUTURE 1 study support the long&#8208;term efficacy, safety, and tolerability of secukinumab in the treatment of patients with PsA.&rdquo;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Five-year Efficacy of Secukinumab in PsA

Psoriatic Arthritis

Patients with psoriatic arthritis (PsA) may observe improved long-term outcomes with secukinumab treatment, according to the results of a five-year study. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe